(Q39194466)

9 September 2017

title

Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer (English)

1 reference

9 September 2017

Le Fu

1

1 reference

9 September 2017

Wei Guo

2

1 reference

9 September 2017

Bingshan Liu

3

1 reference

9 September 2017

Linlin Sun

4

1 reference

9 September 2017

Zhenghong Bi

5

1 reference

9 September 2017

Li Zhu

6

1 reference

9 September 2017

Xinyan Wang

7

1 reference

9 September 2017

Bin Liu

8

1 reference

9 September 2017

Qian Xie

9

1 reference

9 September 2017

Ke Li

10

1 reference

9 September 2017

publication date

1 March 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

18

1 reference

9 September 2017

issue

2

1 reference

9 September 2017

page(s)

126-135

1 reference

c-Met ectodomain shedding rate correlates with malignant potential

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Molecular cloning of a new transforming gene from a chemically transformed human cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Targeting the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.751455

10.3109/1354750X.2012.751455

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference